Genetic Risk for Psychiatric Disorders and Telomere Length
Open Access
- 16 October 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 9, 468
Abstract
Background: Previous studies have revealed associations between psychiatric disorder diagnosis and shorter telomere length. Here, we attempt to discern whether genetic risk for psychiatric disorders, or use of pharmacological treatments (i.e., antidepressants), predict shorter telomere length and risk for aging-related disease in a United Kingdom population sample. Methods: DNA samples from blood were available from 351 participants who were recruited as part of the South East London Community Health (SELCoH) Study, and for which whole-genome genotype data was available. Leukocyte telomere length was characterized using quantitative polymerase chain reactions. Individualized polygenic risk scores for major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SCZ) were calculated using Psychiatric Genomics Consortium summary statistics. We subsequently performed linear models, to discern the impact polygenic risk for psychiatric disorders (an etiological risk factor) and antidepressant use (common pharmacological treatment) have on telomere length, whilst accounting for other lifestyle/health factors (e.g., BMI, smoking). Results: There were no significant associations between polygenic risk for any of the psychiatric disorders tested and telomere length (p > 0.05). Antidepressant use was significantly associated with shorter telomere length and this was independent from a depression diagnosis or current depression severity (p ≤ 0.01). Antidepressant use was also associated with a significantly higher risk of aging-related disease, which was independent from depression diagnosis (p ≤ 0.05). Conclusion: Genetic risk for psychiatric disorders is not associated with shorter telomere length. Further studies are now needed to prospectively characterize if antidepressant use increases risk for aging-related disease and telomere shortening, or whether people who age faster and have aging-related diseases are just more likely to be prescribed antidepressants.Keywords
This publication has 58 references indexed in Scilit:
- Central and non‐central networks, cognition, clinical symptoms, and polygenic risk scores in schizophreniaHuman Brain Mapping, 2017
- Gene expression and proliferation biomarkers for antidepressant treatment resistanceTranslational Psychiatry, 2017
- Telomerase activation as a possible mechanism of action for psychopharmacological interventionsDrug Discovery Today, 2015
- Common polygenic risk for autism spectrum disorder (ASD) is associated with cognitive ability in the general populationMolecular Psychiatry, 2015
- Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in LondonPLOS ONE, 2011
- Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressantsAge and Ageing, 2010
- Telomere length measurement by a novel monochrome multiplex quantitative PCR methodNucleic Acids Research, 2009
- Special Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in SchizophreniaPsychiatric Services, 2006
- Telomeres and human disease: ageing, cancer and beyondNature Reviews Genetics, 2005
- Switching and Signaling at the TelomereCell, 2001